Systemic sclerosis & Raynaud's
Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database.
Main finding · Between-group difference in change in FVC (% predicted)Result — go to the resultAdjusted mean difference in FVC change −2.10 percentage points 95% CI −4.68 to 0.47Authors' conclusion
Adding oral glucocorticoids to ILD-modifying therapy was not associated with improved 12-month FVC in SSc-ILD. Secondary outcomes were sparse and should be interpreted cautiously.
Study context
- Population
- Eligible adults with confirmed SSc-ILD initiating an eligible ILD-modifying therapy at baseline (T0), EUSTAR databasepatients analysed
- Participants
- 443 adults
- Exposure
- Adding oral glucocorticoids to ILD-modifying therapy vs ILD-modifying therapy alone
- ORAL GLUCOCORTICOIDS + ILD-MODIFYING THERAPYn = 185
- ILD-MODIFYING THERAPY ALONEn = 258reference
- Outcome
- Between-group difference in change in FVC (% predicted)
- Follow-up
- 12 months (visit closest to 12 months within a 9 to 15-month window)
Methodological detailsmultiple imputation (m=80), stabilised inverse probability of treatment weighting, robust variance estimators, Rubin's rules
- Multiple imputation (m=80)
- Stabilised inverse probability of treatment weighting
- Robust variance estimators
- Rubin's rules
Main finding
As reported in the abstract
Adjusted mean difference in FVC change
−2.10 percentage points
95% CI −4.68 to 0.47
P = 0.11
ORAL GLUCOCORTICOIDS + ILD-MODIFYING THERAPYvs ILD-MODIFYING THERAPY ALONE
adjusted mean difference in FVC change −2.10 percentage points (95% CI −4.68 to 0.47); P = 0.11
Observational data: associations, not effects.
Secondary outcomes
| Outcome | RR (95% CI) | |
|---|---|---|
| Progressive lung fibrosis (secondary)No clear difference | 1.40 (0.83–2.35) | |
| Isolated DLCO decline ≥15% (secondary)No clear difference | 0.81 (0.39–1.69) | |
| 0.20.5125Relative risk (log scale) |
Original publication
Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database. Arthritis Care Res (Hoboken). Published 11 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →